Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 7/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 2/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23765416 | 1.00 | KCNH2 (0.38) | KCNH2IDH1EPHX2IDH2GRIN2D | |
| SCHEMBL24437109 | 1.00 | KCNH2 (0.38) | KCNH2IDH1EPHX2IDH2GRIN2D | |
| SCHEMBL18927996 | 0.88 | KCNH2 (0.35) | KCNH2 | |
| SCHEMBL17778101 | 0.86 | KCNH2 (0.40) | KCNH2IDH1EPHX2 | |
| SCHEMBL23987150 | 0.86 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL13944829 | 0.82 | IDH1 (0.33) | IDH1EPHX2IDH2 | |
| SCHEMBL18236646 | 0.81 | — | — | |
| SCHEMBL23132219 | 0.81 | IDH1 (0.35) | IDH1EPHX2IDH2 | |
| SCHEMBL25590766 | 0.77 | GNAI3 (0.49) | — | |
| SCHEMBL16748107 | 0.76 | KCNH2 (0.39) | KCNH2EPHX2GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KCNH2 1354/4885IDH1 726/4885EPHX2 3262/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | KCNH2 1354/4885IDH1 726/4885EPHX2 3262/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | KCNH2 1354/4885IDH1 726/4885EPHX2 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.